Conditional survival in breast cancer up to 10 years in the Nordic countries

Author:

Zitricky Frantisek1,Försti Asta23,Hemminki Akseli45ORCID,Hemminki Kari16ORCID

Affiliation:

1. Biomedical Center, Faculty of Medicine Charles University Pilsen Pilsen Czech Republic

2. Hopp Children's Cancer Center (KiTZ) Heidelberg Germany

3. Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) German Cancer Consortium (DKTK) Heidelberg Germany

4. Cancer Gene Therapy Group, Translational Immunology Research Program University of Helsinki Helsinki Finland

5. Comprehensive Cancer Center Helsinki University Hospital Helsinki Finland

6. Division of Cancer Epidemiology German Cancer Research Center (DKFZ) Heidelberg Germany

Abstract

AbstractBackgroundSurvival in breast cancer (BC) has developed favorably but late recurrences are still a problem.MethodsWe model survival data from the NORDCAN database and analyze 1‐, 5‐, and 10‐year relative survival and 5/1‐ and 10/5‐year conditional survival in BC from Denmark (DK), Finland (FI), Norway (NO), and Sweden (SE) between 1971 and 2020. Conditional survival measures survival in those who had survived year 1 to reach year 5 (5/1), or in those who had survived year 5 to reach year 10 (10/5).ResultsAlmost all survival metrics were best for SE but survival in all countries improved in the course of time approaching the SE levels which were 98.3% for 1‐year, 92.3% for 5‐year, and 87.8% for 10‐year survival. Conditional 10/5‐year survival, covering 5 years, was better than 5/1‐year survival, covering 4 years. A contributing factor is most likely the high rate of recurrence in period 2–5 years. The difference was observed for all countries but for DK 10/5‐year survival approached 1‐year survival and for NO and SE 10/5‐year survival was only barely better than 5/1‐year survival. The explanation to this was the excellent 10/5‐year survival in DK compared to SE and particularly to NO. Literature search suggested that the reason for the relatively low 10/5‐year survival in NO might be stagnant survival development in old patients.ConclusionsWe assume that late mortality is critically limiting survival in BC and either interference with the late metastatic process or effective treatment will be key to future improvements in BC survival.

Funder

Horizon 2020 Framework Programme

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3